Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to ...

Generate Biomedicines’ IPO aims to fund Phase 3 GB-0895 for severe asthma/COPD and expand its pipeline. Learn more about GENB ...

Veradermics is set to raise $200 million in an IPO to fund its novel extended-release oral minoxidil for pattern hair loss.

In 2025, the initial public offering (IPO) market continued to rebound from the 2022 and 2023 slump. For the second year in a row, markets saw more IPOs, more special purpose acquisition companies ...

Anaplan, a business-planning software provider owned by private equity firm Thoma Bravo, is taking steps toward an initial ...

Why the IPO market took off in 2025. In this podcast, Motley Fool analysts Emily Flippen and Sanmeet Deo and contirubtor Jason Hall break down why the IPO market took off in 2025, which new listings ...

As I wrote earlier today, private equity firms are sitting on a backlog of software companies they bought during the buyout ...

The IPO market is coming back to life in 2025, fueled by a favorable business climate under President Donald Trump’s second term and a burst in investor demand for new equity stories as risk sentiment ...

SoftBank-backed Lenskart had a muted debut on the exchanges as its shares traded down 11% at the open. The issue was subscribed to over 28 times, with strong participation from institutional investors ...

To unpack what SpaceX’s IPO chatter means, how private liquidity works before a debut, and what investors are looking for in ...

Klarna's bumper IPO demonstrated how Wall Street is becoming more welcoming of sizable fintech listings. That has got market participants wondering which fintech names could be next to go public. "I ...